Liminatus Pharma ( (LIMN) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Liminatus Pharma, a pharmaceutical company, has filed a Form 12b-25 indicating a delay in submitting its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the inability to complete financial statements in time for necessary reviews and signatures before the due date. The company anticipates filing the report within five calendar days following the prescribed due date. There are no expected significant changes in financial results from the corresponding period of the previous fiscal year, and forward-looking statements have been noted. Liminatus Pharma continues to work on compliance efforts, with the notification signed by CEO Chris Kim.
More about Liminatus Pharma
Average Trading Volume: 616,420
Technical Sentiment Signal: Sell
Current Market Cap: $111.5M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.